Benefits and harms of extending the duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stents: a meta-analysis.
Chun Shing KwokHeerajnarain BulluckAlisdair D RydingYoon K LokePublished in: TheScientificWorldJournal (2014)
There are no cardiovascular or mortality benefits associated with extended duration of DAPT, but the risk of major bleeding was significantly lower with shorter lengths of therapy.
Keyphrases
- antiplatelet therapy
- percutaneous coronary intervention
- acute coronary syndrome
- st segment elevation myocardial infarction
- acute myocardial infarction
- st elevation myocardial infarction
- coronary artery disease
- atrial fibrillation
- coronary artery bypass grafting
- cardiovascular events
- coronary artery bypass
- risk factors
- heart failure
- stem cells
- drug induced